Open Biosystems Launches the Collection of Fully Sequenced Assay-Ready cDNAs

Open Biosystems, Inc. has announced the availability of Assay-Ready Complementary DNA (cDNA) based on the industry gold standard Mammalian Gene Collection (MGC).

This is the fully sequenced collection of cDNAs in assay-ready format that is commercially available to the research community and pharmaceutical industry for genome-scale overexpression screening. 

Unlike other lyophilized cDNA plate sets, Open Biosystems' collection is designed to minimize false screening results.

Fully sequenced clones ensure the accurate identification of a gene transcript, thereby generating authentic screening hits that do not require verification by sequencing the full clone insert.

Open Biosystems' Assay-Ready MGC cDNA collection is available as a set of 92, 384-well, microplates containing 6,415 human and 9,624 mouse cDNAs in duplicate.

This allows researchers and scientists to immediately begin the screening process, avoiding bacterial cultures, plasmid preps, normalization, aliquotting and lyophilization. 

"Overexpression with cDNA is a powerful approach to analyzing gene function that, until recently, has been overlooked by researchers," said Troy Moore, CTO of Open Biosystems.

"Our Assay-Ready MGC cDNA offering opens a new realm of possibility for both academic and commercial life science research."

"With our fully sequenced cDNA plate sets, researchers can more quickly and cost-effectively discover the genes underlying disease that may be targeted by therapeutics."

"This coupled with our Expression Arrest product line and Open Access RNAi program underscores our commitment to promoting the flow of research-driven tools and technology to advance medical research."